Carbapenemase Transmission in CREC: Genomic and Epidemiological Insights

Study Background and Research Question

The global spread of carbapenem-resistant Enterobacteriaceae (CRE) presents a major challenge for the treatment of bacterial pneumonia, bronchitis, and other serious infections, especially in hospital settings. Among CRE, carbapenem-resistant Enterobacter cloacae (CREC) has become increasingly problematic due to its rising detection rates and multidrug resistance profiles. The COVID-19 pandemic exacerbated these challenges, with increased antibiotic pressure and complex patient management possibly accelerating the emergence and dissemination of resistance mechanisms. Despite this, detailed investigations into how carbapenemase-encoding genes (CEGs)—the primary drivers of carbapenem resistance—are transmitted and maintained in CREC populations during this period remain scarce. The reference study addressed this knowledge gap by analyzing the prevalence, genomic localization, and mobility of CEGs in CREC isolates from eight teaching hospitals in Guangdong province, China, collected between late 2022 and mid-2024. The research aimed to characterize both the molecular underpinnings and the epidemiological context of resistance gene transmission in this high-risk bacterial species.

Key Innovation from the Reference Study

A major innovation of the study lies in its comprehensive mapping of CEG carriage and movement within a clinically relevant cohort during an unprecedented pandemic era. The researchers identified not only the dominant resistance genes (notably blaNDM-1 and blaIMP) but also provided quantitative data on their chromosomal and plasmid associations. By coupling molecular typing with epidemiological data, the study connects the genetic mechanisms of resistance to patient demographics and hospital department distribution, offering an integrated view of resistance propagation. Crucially, the work demonstrates the high efficiency of horizontal gene transfer for specific carbapenemase genes—particularly those located on plasmids—emphasizing the rapid adaptability and dissemination potential of CREC strains in clinical environments. This approach enables targeted surveillance and highlights the need for robust infection control strategies.

Methods and Experimental Design Insights

The study incorporated several advanced molecular and microbiological techniques to dissect the resistance landscape:

• Samples: 54 CREC isolates were collected from eight teaching hospitals spanning multiple clinical departments, with metadata on patient age, gender, and specimen type.
• Genetic Analysis: Variable temperature SDS plasmid elimination and PCR assays were employed to detect and localize CEGs (including blaNDM-1, blaIMP, and blaKPC-2) on chromosomal or plasmid DNA.
• Antibiotic Susceptibility: Broth microdilution was used to assess resistance profiles against key antibiotics such as imipenem, cefepime, gentamicin, ceftazidime/avibactam, ciprofloxacin, and levofloxacin.
• Plasmid Conjugation: Transfer efficiency of CEGs between strains was quantified via conjugation experiments, with PCR confirmation of successful gene migration.
• Molecular Typing: ERIC-PCR and NTSYS software categorized isolates into genotypes, revealing the clonal structure and possible transmission routes.
• Mobile Genetic Elements: Six types of mobile elements were surveyed, with ISEcp1 being the most prevalent.

This multifaceted approach is notable for directly linking resistance genotype to phenotypic outcomes and transmission potential, supporting both mechanistic and epidemiological interpretations.

Core Findings and Why They Matter

The study found that 85.19% of CREC isolates carried CEGs, with blaNDM-1 being the most common gene. Notably, 33.33% of isolates harbored blaNDM-1 on both chromosomes and plasmids, while nearly half (46.30%) carried it exclusively on plasmids. The presence of blaIMP and blaKPC-2 was less common but still clinically significant. Resistance phenotypes were strongly associated with CEG carriage: isolates with CEGs showed significantly higher resistance to imipenem, cefepime, ceftazidime/avibactam, and other agents, underscoring the threat to current therapy options for Gram-negative bacterial infection research and clinical management. Plasmid conjugation experiments confirmed that over 95% of CEGs could be successfully transferred between strains, supporting rapid horizontal spread. The identification of ISEcp1 and multiple mobile elements in these plasmids further highlights the genetic plasticity driving resistance. Epidemiologically, the study identified higher detection rates of CEG-positive CREC among male and elderly patients, within respiratory medicine departments, and in sputum samples—contexts directly relevant to the treatment of bacterial pneumonia and bronchitis. Molecular typing revealed the coexistence of multiple genotypes across departments and hospitals, with some genotypes (type E and G) being particularly prevalent, suggesting both clonal expansion and horizontal gene transfer as routes for dissemination.

Protocol Parameters

• Sample collection: For translational models, prioritize sputum and respiratory samples in elderly male cohorts to reflect epidemiological hotspots.
• Plasmid elimination: Variable temperature SDS methods, as described in the reference, effectively distinguish plasmid- versus chromosome-encoded resistance genes.
• Antibiotic susceptibility testing: Use broth microdilution with a focus on cephalosporins (such as ceftazidime), carbapenems, and aminoglycosides to capture multidrug resistance phenotypes.
• Conjugation assays: Implement PCR confirmation post-conjugation to validate horizontal gene transfer events.
• Molecular typing: Apply ERIC-PCR and clustering analysis to monitor clonal spread and genotype diversity.

Comparison with Existing Internal Articles

Recent internal reviews, such as "Ceftazidime: Translational Insights for Gram-Negative Resistance", complement the reference study by highlighting the clinical and experimental strategies for addressing β-lactamase-mediated resistance in Gram-negative bacteria. These articles emphasize the importance of third-generation cephalosporins like ceftazidime as both therapeutic agents and research tools, especially in the context of evolving resistance mechanisms such as those detailed for CREC. The "Ceftazidime in Translational Research" review extends this analysis by providing workflow strategies for monitoring resistance transmission and designing protocols suited to multidrug-resistant pathogens—a direct extension of the reference study’s findings. The "Transmission Dynamics of Carbapenemase Genes in CREC in China" article specifically reinforces the importance of plasmid-borne CEGs and their epidemiological implications, echoing the reference study's focus on the dominance of blaNDM-1 and the frequent occurrence of multiple mobile genetic elements.

Limitations and Transferability

While the study provides a robust framework for understanding CEG transmission in CREC, several limitations should be considered. The sample size, though diverse, is limited to eight hospitals in one region of China and may not capture the full geographic or temporal variability of resistance dynamics. The focus on the COVID-19 era is contextually valuable but may reflect unique antibiotic usage patterns and infection control practices that differ from pre- or post-pandemic scenarios. Moreover, while molecular methods accurately identified gene localization and transfer, functional validation of resistance in clinical outcomes was not addressed. Transferability to other settings or bacterial species should be approached with these caveats in mind. Nonetheless, the protocol and surveillance recommendations are broadly applicable to Gram-negative infection research, including investigations into Pseudomonas aeruginosa infection and other nosocomial threats.

Research Support Resources

For laboratories modeling multidrug-resistant Gram-negative infections or studying β-lactamase resistance mechanisms, reliable antibiotic standards are essential. Researchers can use Ceftazidime (SKU B3539), a third-generation cephalosporin with strong activity against Pseudomonas aeruginosa and resistance to β-lactamase hydrolysis, to support phenotypic screening, resistance modeling, and protocol development in line with the workflows described in this and related studies. APExBIO provides detailed storage and solubility information to facilitate reproducible results in both in vitro and in vivo settings.